Intrinsiqq
Oculis Holding AG logo

Oculis Holding AG Financials

OCS

Compare

All currency values in CHF millions unless otherwise noted

Scroll

Income Statement
TTM
DEC 2025
DEC 2024
DEC 2023
DEC 2022
DEC 2021
Revenues
RevenueCHF 0CHF 0CHF 0CHF 0CHF 0CHF 0
Operating Income-CHF 86-CHF 82-CHF 73-CHF 46-CHF 32-CHF 13
Non-Operating
Net Interest Expense-CHF 1-CHF 1-CHF 1-CHF 1-CHF 6-CHF 5
Income Tax Expense-CHF 0-CHF 0-CHF 0CHF 0CHF 0CHF 0
Net Income
Net Income-CHF 79-CHF 99-CHF 86-CHF 89-CHF 39-CHF 19
Per Share Data
Revenue Per ShareCHF 0.00CHF 0.00CHF 0.00CHF 0.00––
EPS (Basic)-CHF 1.39-CHF 1.89-CHF 2.12-CHF 2.97––
EPS (Diluted)-CHF 1.39-CHF 1.89-CHF 2.12-CHF 2.97––
Shares Outstanding61.3M52.2M40.4M26.4M––
Dividends Per ShareCHF 0.00CHF 0.00––––

Oculis Holding (OCS) financials: revenue, profit and margins

Oculis Holding (OCS) generated about CHF 0.00 in revenue and -CHF 79 million in net income over the trailing twelve months. Figures are from company filings; this is analysis, not investment advice.

Frequently asked

What is Oculis Holding's (OCS) revenue?+

Oculis Holding generated about CHF 0.00 in revenue over the trailing twelve months. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Is Oculis Holding profitable?+

Oculis Holding reported about -CHF 79 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How the market compares: How many US companies are profitable

Peers

Biotechnology · Pick stocks to compare with OCS

CompareIntrinsic value
NEWBRY.XSTONewbury Pharmaceuticals AB
€0.11+0.91%40
HPHA.XETRHeidelberg Pharma AG
€2.01-2.90%10
MEDCL.XPARMedincell SA
€26.70-2.05%40
ZTEKZentek Ltd.
€0.33-0.60%40
XTXXFAdastra Holdings Ltd.
€0.08+0.00%40
XRTXXORTX Therapeutics Inc.
$0.84-5.73%10
VALNValneva SE Sponsored ADR
$5.16-3.82%0
TRIBTrinity Biotech plc Sponsored ADR
$6.24+13.66%10

Held by ETFs

OCS is in 4 US ETFs. The largest of them, with OCS's weight in each:

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing OCS

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.